Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.26−0.03 (-0.20%)
Close on Nov 18, 2026Market cap $82.16MP/E 3.3Yield –
Rallybio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Rallybio's operating cash flow for the twelve months ending Sep 30, 2026 was $30.99M. For fiscal 2025 it was -$29.81M. The highest annual figure on record is -$22.04M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.81M | – |
| FY2024 | Dec 31, 2024 | -$49.28M | – |
| FY2023 | Dec 31, 2023 | -$60.27M | – |
| FY2022 | Dec 31, 2022 | -$57.28M | – |
| FY2021 | Dec 31, 2021 | -$45.53M | – |
| FY2020 | Dec 31, 2020 | -$22.04M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.28M | – |
| Q2 FY2026 | Jun 30, 2026 | $45.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.21M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.74M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.87M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.85M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.62M | – |
See a number that looks wrong?